# Relates to the availability of opioid reversal agents

**Bill ID:** A8075DC
**Session:** 2024
**Sponsor:** Phil Steck
**Status:** In Senate Committee
**PDF:** [A8075DC PDF](https://legislation.nysenate.gov/pdf/bills/2024/A8075DC)

## Summary

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  8075--C
 
  2023-2024 Regular Sessions
 
  I N  A S S E M B L Y
 
  September 27, 2023
  ___________
 
 Introduced  by  M.  of  A.  STECK, FAHY -- read once and referred to the
  Committee on Alcoholism and Drug Abuse -- committee  discharged,  bill
  amended,  ordered reprinted as amended and recommitted to said commit-
  tee -- again reported from said  committee  with  amendments,  ordered
  reprinted  as amended and recommitted to said committee -- recommitted
  to the Committee on Alcoholism  and  Drug  Abuse  in  accordance  with
  Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered
  reprinted as amended and recommitted to said committee
 
 AN  ACT  to  amend  the mental hygiene law and the public health law, in
  relation to the availability of opioid reversal agents
 
  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. Subdivision (l) of section 19.09 of the mental hygiene law,
 as  added  by  chapter  434  of  the laws of 2021, is amended to read as
 follows:
  (l)(1) The office, in consultation  with  the  department  of  health,
 shall  maintain  on  its  website  a publicly available directory of all
 distributors of opioid [antagonists]  REVERSAL  AGENTS  to  the  public,
 including  but  not limited to, pharmacies, prevention programs and not-
 for-profits. As used in this subdivision, the following terms shall have
 the following meanings:
  (i) "Opioid" means  an  opiate  as  defined  in  section  thirty-three
 hundred two of the public health law.
  (ii)  "Opioid  [antagonist]  REVERSAL AGENTS" means a federal food and
 drug administration-approved drug that, when  administered,  negates  or
 neutralizes in whole or in part the pharmacological effects of an opioid
 in  the  body.  The  [opioid  antagonist shall be limited to naloxone or
 other medications approved by the department of health for this purpose]
 DEPARTMENT OF HEALTH SHALL MAKE AVAILABLE ANY FORMULATION AND DOSAGE  OF
 OPIOID  REVERSAL  AGENTS  THAT ARE APPROVED BY THE FEDERAL FOOD AND DRUG
 ADMINISTRATION.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD11983-04-4
 A. 8075--C  2
 
  (2) The directory required by this subdivision shall  include  and  be
 searchable by the following information:
  (i)  addresses  of  each  distributor of opioid [antagonists] REVERSAL
 AGENTS;
  (ii) contact information, such as phone numbers  or  email  addresses,
 for each distributor;
  (iii)  services  offered  by each distributor at each location if more
 than one, as well as information providing  which  opioid  [antagonists]
 REVERSAL AGENTS are currently available at each distributor;
  (iv) special populations served;
  (v) insurance providers accepted;
  (vi) hours of operation of each distributor;
  (vii) contact information of opioid addiction prevention programs; and
  (viii) any other information the commissioner deems necessary.
  (3)  The  office  may  utilize  an  existing  directory to satisfy the
 requirements of this subdivision.
  (4) THE OFFICE SHALL ALLOW FOR CHOICE OF ANY FORMULATION AND DOSAGE OF
 OPIOID REVERSAL AGENTS THAT ARE APPROVED BY THE FEDERAL  FOOD  AND  DRUG
 ADMINISTRATION  IN  THE  PURCHASE,  DISTRIBUTION  OR  AUTHORIZATION  TO
 PRESCRIBE OR DISPENSE SUCH PRODUCTS.
  ยง 2. Subdivision (b) of section 25.18 of the  mental  hygiene  law  is
 amended by adding a new paragraph 4 to read as follows:
  4.  ANY EXPENDITURE USED FOR THE PURCHASE OR DISTRIBUTION OF AN OPIOID
 REVERSAL AGENT, AS DEFINED IN SUBPARAGRAPH  (II)  OF  PARAGRAPH  ONE  OF
 SUBDIVISION  (L)  OF SECTION 19.09 OF THIS TITLE, SHALL ALLOW FOR CHOICE
 OF ANY FORMULATION OR DOSAGE THAT IS APPROVED BY THE  FEDERAL  FOOD  AND
 DRUG ADMINISTRATION.
  ยง  3.  Subparagraph  (i)  of paragraph (a) of subdivision 3 of section
 3309 of the public health law, as amended by chapter 42 of the  laws  of
 2014, is amended to read as follows:
  (i) "Opioid [antagonist] REVERSAL AGENTS" means a drug approved by the
 Food  and  Drug  Administration  that,  when  administered,  negates  or
 neutralizes in whole or in part the pharmacological effects of an opioid
 in the body. ["Opioid antagonist reversal agents" shall  be  limited  to
 naloxone  and  other  medications  approved  by  the department for such
 purpose] THE DEPARTMENT SHALL MAKE AVAILABLE ANY FORMULATION AND  DOSAGE
 OF OPIOID REVERSAL AGENTS THAT ARE APPROVED BY THE FEDERAL FOOD AND DRUG
 ADMINISTRATION.
  ยง  4. Section 3309 of the public health law is amended by adding a new
 subdivision 9 to read as follows:
  9. ANY PURCHASE, DISTRIBUTION OR AUTHORIZATION TO  PRESCRIBE  PURSUANT
 TO THIS SECTION BY THE COMMISSIONER SHALL ALLOW FOR CHOICE OF ANY FORMU-
 LATION  OR DOSAGE THAT IS APPROVED BY THE FEDERAL FOOD AND DRUG ADMINIS-
 TRATION.
  ยง 5. This act shall take effect immediately.